New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy

Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided.

Detalles Bibliográficos
Autores principales: Guida, Agostino, Perri, Francesco, Ionna, Franco, Ascierto, Paolo A., Grimaldi, Antonio M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813008/
https://www.ncbi.nlm.nih.gov/pubmed/33489133
http://dx.doi.org/10.1002/ccr3.3418
_version_ 1783637772620267520
author Guida, Agostino
Perri, Francesco
Ionna, Franco
Ascierto, Paolo A.
Grimaldi, Antonio M.
author_facet Guida, Agostino
Perri, Francesco
Ionna, Franco
Ascierto, Paolo A.
Grimaldi, Antonio M.
author_sort Guida, Agostino
collection PubMed
description Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided.
format Online
Article
Text
id pubmed-7813008
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78130082021-01-22 New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy Guida, Agostino Perri, Francesco Ionna, Franco Ascierto, Paolo A. Grimaldi, Antonio M. Clin Case Rep Case Reports Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided. John Wiley and Sons Inc. 2020-12-02 /pmc/articles/PMC7813008/ /pubmed/33489133 http://dx.doi.org/10.1002/ccr3.3418 Text en © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Guida, Agostino
Perri, Francesco
Ionna, Franco
Ascierto, Paolo A.
Grimaldi, Antonio M.
New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy
title New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy
title_full New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy
title_fullStr New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy
title_full_unstemmed New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy
title_short New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy
title_sort new‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (mronj): late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813008/
https://www.ncbi.nlm.nih.gov/pubmed/33489133
http://dx.doi.org/10.1002/ccr3.3418
work_keys_str_mv AT guidaagostino newgenerationanticancerdrugsandmedicationrelatedosteonecrosisofthejawmronjlateonset3yearsafteripilimumabendovenousadministrationwithapossibleroleoftargettherapy
AT perrifrancesco newgenerationanticancerdrugsandmedicationrelatedosteonecrosisofthejawmronjlateonset3yearsafteripilimumabendovenousadministrationwithapossibleroleoftargettherapy
AT ionnafranco newgenerationanticancerdrugsandmedicationrelatedosteonecrosisofthejawmronjlateonset3yearsafteripilimumabendovenousadministrationwithapossibleroleoftargettherapy
AT asciertopaoloa newgenerationanticancerdrugsandmedicationrelatedosteonecrosisofthejawmronjlateonset3yearsafteripilimumabendovenousadministrationwithapossibleroleoftargettherapy
AT grimaldiantoniom newgenerationanticancerdrugsandmedicationrelatedosteonecrosisofthejawmronjlateonset3yearsafteripilimumabendovenousadministrationwithapossibleroleoftargettherapy

Ejemplares similares